Table 1 Clinical characteristics and drugs used in the successful and unsuccessful treatment outcome groups

Health education ^a

168 (56.2)

57 (38.8)

< 0.001

Sex ^a

< 0.001

female

109 (36.5)

25 (17)

male

190 (63.5)

122 (83)

Age(years)^b

34.9 ± 13.8

44.7 ± 15.4

< 0.001

Address ^a

0.653

Xi’an

124 (41.5)

65 (44.2)

Other regions

175 (58.5)

82 (55.8)

BMI(kg/m²)^b

20.3 ± 2.8

20.1 ± 2.9

0.509

Marriage ^a

0.03

married

185 (61.9)

107 (72.8)

single

114 (38.1)

40 (27.2)

Grade of smear ^a

0.007

0

137 (45.8)

45 (30.6)

1

72 (24.1)

34 (23.1)

2

31 (10.4)

22 (15)

3

30 (10)

19 (12.9)

4

29 (9.7)

27 (18.4)

Drug sensitivity test

Fluoroquinolones ^a

0.448

sensitive

229 (76.6)

107 (72.8)

resistant

70 (23.4)

40 (27.2)

Injectable agents ^a

0.902

sensitive

289 (96.7)

141 (95.9)

resistant

10 (3.3)

6 (4.1)

Cavity ^a

195 (65.2)

90 (61.2)

0.471

Lung Lesions (field) ^b

2.8 ± 1.7

3.8 ± 1.8

< 0.001

Treatment history ^a

< 0.001

New case

176 (58.9)

60 (40.8)

Previously treated

123 (41.1)

87 (59.2)

Diabetes mellitus ^a

35 (11.7)

35 (23.8)

0.002

Drugs used in regimen

Fluoroquinolones ^a

255 (85.3)

118 (80.3)

0.227

Linezolid ^a

74 (24.7)

39 (26.5)

0.771

Cycloserine ^a

228 (76.3)

104 (70.7)

0.255

Clofazimine ^a

22 (7.4)

14 (9.5)

0.546

Ethambutol ^a

124 (41.5)

57 (38.8)

0.658

Pyrazinamid ^a

294 (98.3)

145 (98.6)

1

injectable agents ^a

290 (97)

141 (95.9)

0.582

Prothionamide ^a

271 (90.6)

135 (91.8)

0.809

P-aminosalicylate ^a

16 (5.4)

14 (9.5)

0.146